Compass Pathways' 1-Year Psilocybin Data: Implications for U.S. Policy

Compass Pathways' One-Year Psilocybin Data: Durable Relief in Depression

Compass Pathways announced on September 9, 2026, that its phase 3 clinical trial of COMP360 psilocybin therapy for treatment-resistant depression (TRD) demonstrated sustained symptom relief at the one-year mark. According to the company’s release, participants who responded to a single 25mg psilocybin session maintained clinically meaningful improvements in depressive symptoms over 12 months, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS). This is the first large-scale, placebo-controlled study to report such long-term durability for a psychedelic intervention in a psychiatric population. Primary source: Compass Pathways.

Mechanism, Study Design, and Context

Psilocybin, a serotonergic psychedelic, is believed to exert its antidepressant effects by modulating 5-HT2A receptors and promoting neuroplasticity. The COMP360 trial (NCT04593563) enrolled over 900 adults with TRD across multiple U.S. and European sites. After a single dose of 25mg COMP360 psilocybin administered in a controlled setting with psychological support, patients were followed for up to 12 months. The primary endpoint at week 6 showed statistically significant improvements versus placebo; the new data extend this effect, with 34% of initial responders remaining in remission at one year. Notably, the study protocol included safety monitoring and structured integration sessions, reflecting best practices for psychedelic-assisted therapy.

Regulatory, Payer, and Policy Implications

The availability of one-year efficacy data is a critical milestone for U.S. Food and Drug Administration (FDA) review, as durable benefit is a key criterion for novel psychiatric therapeutics. The FDA’s Breakthrough Therapy designation for COMP360 (granted in 2018) was contingent on early signals of rapid and robust efficacy, but long-term data are essential for approval and labeling decisions. Payers and insurers also require evidence of sustained benefit to justify coverage of high-touch, resource-intensive therapies. This dataset will likely inform both the FDA’s risk-benefit assessment and reimbursement negotiations with major payers. In addition, the results may influence state-level policy debates on psychedelic access, as seen in recent legislative activity in Oregon, Colorado, and California.

• Non-obvious implication: The durability of response may shift clinical trial designs for other psychedelic compounds, prompting sponsors to collect longer-term data and potentially raising the bar for regulatory approval in this class.

Risks, Unknowns, and Limitations

While the one-year data are promising, several risks and unknowns remain. Adverse events, though generally mild to moderate and transient, included transient anxiety, headache, and occasional suicidal ideation, underscoring the need for rigorous screening and support. The durability of response was limited to a subset of initial responders; about two-thirds of patients did not maintain remission at one year, highlighting the heterogeneity of effect. Moreover, the trial’s highly controlled setting may not reflect real-world practice, where therapist training, integration protocols, and patient selection vary widely. Long-term safety, especially regarding repeated dosing or off-label use, remains to be established. Finally, the absence of active comparator arms (such as standard antidepressants or psychotherapy) limits conclusions about relative efficacy.

Outlook: Shaping the Future of Psychedelic Medicine

The release of one-year follow-up data from Compass Pathways’ COMP360 program marks a pivotal moment for psychedelic research and policy in the United States. These results will likely accelerate regulatory and payer deliberations, inform clinical guidelines, and set new expectations for evidence standards in the field. As other sponsors (including Usona Institute and MAPS Public Benefit Corporation) advance their own late-stage trials, the demand for long-term, comparative, and real-world data will only increase. Stakeholders should monitor forthcoming FDA advisory committee meetings and potential updates to federal and state scheduling laws. Ultimately, the integration of durable efficacy data into policy and practice will determine the pace and scope of psychedelic medicine’s adoption in mainstream mental health care.

How we research: This article was written by Dr. Alex Kim, PhD (Neuroscience, Policy Editor), and reviewed by Dr. Maya Patel, MD, on 2026-09-10. Primary sources include Compass Pathways’ press release and FDA documentation.